• Vaccine Name: T. cruzi vaccine using attenuated Salmonella expressing T. cruzi Cruzipain
• Target Pathogen: Trypanosoma cruzi
• Target Disease: Chagas disease
• Vaccine Ontology ID: VO_0001393
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: mouse
• Cruzipain gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001147
• Immunization Route: Intranasally

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were vaccinated four times intranasally with control and cruzipain-expressing salmonella cells. The mice were lightly anesthetized with ketamine-xylazine given intraperitoneally, and salmonella vaccines were administered in 10-μl volumes of PBS. A total of 2 × 10^6 CFU of salmonella was given for primary vaccinations, and 2 × 10^7 CFU of salmonella was given for booster vaccinations. The second vaccinations were given 4 weeks after the priming doses, and the three booster vaccinations were given at 2-week intervals (Schnapp et al., 2002).
• Challenge Protocol: One month after the final vaccinations, the mice were challenged orally with 2,000 T. cruzi IMT (Schnapp et al., 2002).
• Efficacy: As early as 15 days after immunization, the parasitemias detected in the cruzipain-immunized group were significantly lower than those in the phage10-immunized and unimmunized groups. Significantly reduced parasitemias persisted in the cruzipain-immunized group throughout the remainder of the first month postchallenge (Schnapp et al., 2002).